Detailed Abstract
[BP Oral Presentation 3 - Pancreas Disease/Surgery]
[BP OP 3-3] Validation of american joint committee on cancer (AJCC) 8th edition for pancreatic neuroendocrine tumor
In Woong HAN1, Yunghun YOU1,2, Dong Wook CHOI1, Seong Ho CHOI1, Jin Seok HEO1, Youngju RYU1, Dae Joon PARK1
1Departments of Surgery, Samsung Medical Center Sungkyunkwan University College of Medicine, Korea
2Department of Surgery, Konkuk University Choongju Hospital, Konkuk University School of Medicine, Korea
Introduction : The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for pancreatic neuroendocrine tumor (NET) included several significant changes. This study aim to evaluate this staging system compared to the 7th edition AJCC staging system.
Methods : Using Korean tumor registry system – Bilary pancreas (KOTUS-BP) database (2000-2014), 486 patients who underwent surgery for nonfunctional neuroendocrine tumor of pancreas were identified. Except for 39 (8.0%) cases with grade 3 (G3), 447 patients with G1, G2 were included in this study. Overall survival and disease free survival were calculated using the Kaplan-Meier method and compared by log-rank tests.
Results : Poor discrimination in 10 years overall survival rate was noted between stage III and IV. There was 10-year disease free survival discrimination by stage: I, 93.2%; II, 83.1%; III, 38.9%; IV, 0.0% (p < .0001). Significant difference in 10 years disease free survival rate existed according to T stage (T1 93.3% vs. T2 84.8% vs. T3 53.3% vs. T4 36.0%; p < 0.001) and grade (G1 91.9% vs. G2 39.4%; p < 0.001). There was significant difference in 10 years overall survival rate between N0 versus N1 (84.4% vs. 56.3%; p = 0.001).
Conclusions : This is the first large-scale validation of the AJCC 8th edition staging system for pancreatic neuroendocrine tumor. The revised 8th system provides better discrimination compared to that of the 7th-edition system.
Methods : Using Korean tumor registry system – Bilary pancreas (KOTUS-BP) database (2000-2014), 486 patients who underwent surgery for nonfunctional neuroendocrine tumor of pancreas were identified. Except for 39 (8.0%) cases with grade 3 (G3), 447 patients with G1, G2 were included in this study. Overall survival and disease free survival were calculated using the Kaplan-Meier method and compared by log-rank tests.
Results : Poor discrimination in 10 years overall survival rate was noted between stage III and IV. There was 10-year disease free survival discrimination by stage: I, 93.2%; II, 83.1%; III, 38.9%; IV, 0.0% (p < .0001). Significant difference in 10 years disease free survival rate existed according to T stage (T1 93.3% vs. T2 84.8% vs. T3 53.3% vs. T4 36.0%; p < 0.001) and grade (G1 91.9% vs. G2 39.4%; p < 0.001). There was significant difference in 10 years overall survival rate between N0 versus N1 (84.4% vs. 56.3%; p = 0.001).
Conclusions : This is the first large-scale validation of the AJCC 8th edition staging system for pancreatic neuroendocrine tumor. The revised 8th system provides better discrimination compared to that of the 7th-edition system.
SESSION
BP Oral Presentation 3
Room C 3/30/2018 5:00 PM - 5:50 PM